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Abstract
Introduction: Diffuse intrinsic pontine glioma (DIPG) and midline high-grade glioma (mHGG) are lethal childhood
brain tumors. Spatial genomic heterogeneity has been well-described in adult HGG but has not been comprehensively
characterized in pediatric HGG. We performed whole exome sequencing on 38-matched primary, contiguous, and
metastatic tumor sites from eight children with DIPG (n = 7) or mHGG (n = 1) collected using a unique MRI-guided
autopsy protocol. Validation was performed using Sanger sequencing, Droplet Digital polymerase-chain reaction,
immunohistochemistry, and fluorescent in-situ hybridization.
Results: Median age at diagnosis was 6.1 years (range: 2.9–23.3 years). Median overall survival was 13.2 months
(range: 11.2–32.2 months). Contiguous tumor infiltration and distant metastases were observed in seven and six
patients, respectively, including leptomeningeal dissemination in three DIPGs. Histopathological heterogeneity was
evident in seven patients, including intra-pontine heterogeneity in two DIPGs, ranging from World Health
Organization grade II to IV astrocytoma. We found conservation of heterozygous K27M mutations in H3F3A (n = 4)
or HIST1H3B (n = 3) across all primary, contiguous, and metastatic tumor sites in all DIPGs. ACVR1 (n = 2), PIK3CA
(n = 2), FGFR1 (n = 2), and MET (n = 1) were also intra-tumorally conserved. ACVR1 was co-mutated with HIST1H3B
(n = 2). In contrast, PDGFRA amplification and mutation were spatially heterogeneous, as were mutations in BCOR
(n = 1), ATRX (n = 2), and MYC (n = 1). TP53 aberrations (n = 3 patients) varied by type and location between
primary and metastatic tumors sites but were intra-tumorally conserved.
Conclusion: Spatial conservation of prognostically-relevant and therapeutically-targetable somatic mutations in
DIPG and mHGG contrasts the significant heterogeneity of driver mutations seen in adult HGG and supports
uniform implementation of diagnostic biopsy in DIPG and mHGG to classify molecular risk groups and guide
therapeutic strategy.
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Introduction
Diffuse intrinsic pontine glioma (DIPG) is an aggressive
pediatric brain tumor with a median survival of less than
1 year, despite current multimodal therapies [1, 2].
Midline, non-brainstem high-grade gliomas (mHGGs)
in children share clinical and biological features with
DIPG and have a similarly dismal prognosis [3–5]. Histor-
ically, reluctance to biopsy these precariously located tu-
mors to obtain tissue has impeded the understanding of
their biology. Recently, greater acceptance of the safety of
biopsy [6–9], development of autopsy-based protocols
[10–12], and advancement of high-throughput sequencing
technology have enabled unprecedented insight into the
molecular underpinnings of DIPG and mHGG. Genomic
studies have detailed recurrent aberrations in many canon-
ical cancer pathways and mutations in novel oncogenes,
such as highly recurrent histone mutations (H3F3A or
HIST1H3B/C/I) and ACVR1 [5, 10, 13, 14].
Despite remarkable genomic discoveries, therapeutic
progress for DIPG and mHGG has remained static. The
standard treatment, focal radiotherapy, provides only
transient local control and fails to address the recently
reported metastatic potential of these highly infiltrative
tumors [1, 15, 16]. Clinical trials of adjuvant chemother-
apy and targeted therapy, including those targeting crit-
ical pathways, such as platelet-derived growth factor
receptor alpha (PDGFRA) [7–9, 17], have not improved
outcome over many decades [11, 12, 18]. Intra-tumoral
genomic heterogeneity and clonal evolution are well-
recognized in the pathogenesis and therapeutic resist-
ance of adult HGG [19–21]. We previously reported
intra-tumoral histopathological variation in DIPGs from
autopsy [1]. However, evaluation of spatial genomic
heterogeneity, which carries important implications
for determining the generalizability of molecular profiles
derived from small diagnostic biopsies and scientifically-
sound integration of molecularly-targeted therapies, has
not been reported in DIPG or mHGG. We used whole
exome sequencing (WES) to comprehensively evaluate
spatial intra-tumoral genomic heterogeneity in eight chil-
dren with DIPG or mHGG.
Materials and methods
Patient cohort
Tissue samples (n = 38) and clinical data were obtained
from eight patients with DIPG (n = 7) or mHGG (n = 1)
consented to the IRB-approved Pediatric Brain Tumor
Repository (PBTR) autopsy protocol (Study: 2013–1245)
at Cincinnati Children’s Hospital Medical Center from
2013–2014. Diagnosis of DIPG was based on rapidly
progressive clinical symptoms and imaging characteristics
on pre-treatment magnetic resonance imaging (MRI) (in-
filtrative tumor involving at least two-thirds of the pons).
One patient with a bi-thalamic tumor underwent biopsy
(not sequenced); no DIPGs were biopsied. Diagnostic and
post-mortem imaging for all patients was centrally
reviewed by one neuro-radiologist (J.L.).
Autopsy protocol
Median time from death to autopsy was 11.8 h (range:
4.8–20 h). Time to autopsy did not affect the quality or
quantity of DNA. Normal brain and tumor visible on
gross examination, including at least two locations in the
pons (usually left anterior and right posterior), were
sampled when the brain was harvested from the calvar-
ium. After harvest, the whole brain was fixed in forma-
lin. Ex-vivo MRI was performed on the fixed whole
brain of seven patients (Patient 5 not imaged due to
poor anatomical configuration after harvest) using a 1.5-
Tesla MR system employing high-resolution volumetric
T1- and T2-weighted images. 3D renderings were per-
formed to optimize orientation of gradient-echo T1.
Coronal and axial oblique images were obtained on the
cerebrum and cerebellum, respectively. Volumetric data
sets were reconstructed into standard anatomic orienta-
tions, and all attempts were made to duplicate standard
in vivo slice orientation for planar data sets. The path-
ologist (L.M.) and neuro-radiologist jointly reviewed
hematoxylin & eosin (H&E) sections and MRI images to
determine contiguous and metastatic tumor locations.
Tumor was classified as “primary” if located within the
pons (or thalamus in Patient 8), “contiguous” if involving
a CNS structure adjoining the primary tumor, or “meta-
static” if involving a non-contiguous CNS structure.
Routine sections of the frontal lobe, cerebellar cortex, all
deep gray nuclei of cerebrum/cerebellum, and all brain-
stem structures were taken regardless of gross and/or
MRI abnormalities. Two neuropathologists (L.M., C.H.)
independently reviewed each tumor sample to assign
histology, grade, and tumor percentage. To ensure ad-
equate tumor content (Fig. 1), H&E slides were reviewed
from each frozen specimen, the initial cut of each
formalin-fixed paraffin-embedded (FFPE) block, and an
additional cut of FFPE block after scrolls were obtained
for DNA extraction.
Whole exome sequencing alignment and structural
variants
DNA extraction was performed on frozen tissue as pre-
viously described [22] and on FFPE tissue using Bio-
chain’s FFPE Tissue DNA Extraction Kit (#K5019100).
Library preparation and WES were performed at BGI
Americas using the Agilent SureSelect Human All Exon
V5 Kit and Illumina HiSeq 2500 using V3 chemistry,
respectively. All samples were sequenced at an average
depth of 100× (4 samples per lane generating 12 Gb of
raw data per sample). The Burrows-Wheeler Aligner
[23] tool was used to map all reads to the human
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genome build GRCh37/hg19. The GATK variant calling
pipeline was followed to identify single nucleotide poly-
morphisms. MuTect 1.1.4 was used to detect somatic
single nucleotide variants (SNVs) in 46 candidate genes
with clinical significance (Additional file 1: Table S1).
Variants with sufficient coverage were further annotated
using Annovar and SNPeff, giving RefSeq gene annota-
tions, amino acid changes, ExAC SIFT, PolyPhen, LTR
and MutationTaster scores.
Histology and immunohistochemistry
H&E staining and p53 immunohistochemistry (IHC)
[p53 (DO-7) primary mouse antibody 790–2912] were
performed on 4 μm paraffin sections mounted on posi-
tively charged slides. Immuno-detection was performed
as previously described [1].
Sanger sequencing and droplet digital polymerase-chain
reaction
H3F3A and HIST1H3B were partially sequenced as
described by Wu et al. [1, 24] (Additional file 2: Table
S2). Somatic SNVs identified by WES were validated
using Droplet Digital PCR System according to manu-
facturer instructions (BioRad, Mississauga, Canada)
(Additional file 3: Table S3). Samples were read in
duplicate, and data were considered if at least 100
droplets contained fluorescent signal from either VIC
or FAM channels in both duplicates. Samples were
considered positive for mutation if at least 10 positive
droplets were detected in the mutant channel (FAM).
Mutational allele frequencies were estimated using a
ratio between the mutant channel signal and total
positive droplet counts.
Florescence in-situ hybridization
Florescence in-situ hybridization (FISH) for PDGFRA
(Empire Genomics dual-color break apart probe) and
c-MYC (Abbott Molecular dual-color break apart probe)
was performed on 4 μm paraffin sections mounted on
positively charged slides with DAPI II counterstain.
Statistics
Bioinformatic methods are described above. Descriptive
statistics were used to report the frequency of genetic
changes across disease locations.
Results
Clinical and histopathological characteristics
Patient characteristics and treatment data are listed in
Table 1. Median age at diagnosis was 6.1 years (range:
Fig. 1 Spatial histopathological and genomic landscape of DIPG and mHGG in children. Histology and WHO grade were frequently heterogeneous
within the pons or between the pons and contiguous or metastatic sites. Somatic mutations (indicated by a black box or stripped overlay of a colored
box if co-existing with a copy number change) in H3F3A (H3.3), HIST1H3B (H3.1), ACVR1, PIK3CA, FGFR1, and MET were conserved across all disease sites.
Somatic mutations in ATRX, BCOR, MYC, and PDGFRA and PDGFRA amplification were spatially heterogeneous. WHO =World Health Organization,
FFPE = formalin-fixed paraffin-embedded
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2.9-23.3 years); median overall survival (OS) was
13.2 months (range: 11.2–32.2 months). Median time
between the last pre- and post-mortem imaging was
46 days (range: 28–448 days). Only Patient 1 had evi-
dence of distant metastases on pre-mortem imaging
(5 months after diagnosis). Primary tumors were glioblast-
oma (GBM, n = 7) or anaplastic astrocytoma (AA, n = 1)
(Fig. 1). Intra-tumoral histopathological heterogeneity was
observed in the primary tumor of seven of eight patients,
including the primary tumor in Patient 1 that demon-
strated regions with WHO grade II, III, and IV astrocy-
toma. The histological grade of primary and metastatic
sites varied in four of five DIPG patients with metastatic
disease. Intracranial leptomeningeal dissemination was
observed in three of seven DIPGs (leptomeningeal disease
for Patient 1 was not sequenced) (Fig. 1).
Lack of heterogeneity in core gene set supports their role
as driver mutations and potential therapeutic targets
Relevant genomic findings are summarized in Fig. 1.
Heterozygous H3K27M mutations were detected by
WES across all primary, contiguous, and metastatic dis-
ease sites in all seven DIPG patients and were validated
by ddPCR (Additional file 4: Table S4) and Sanger
sequencing (Additional file 5: Figure S1). H3.3-K27M
was found in four DIPGs and co-occurred with PDGFRA
amplification and TP53 aberrations in two cases, an as-
sociation we previously described [14, 22]. ACVR1 muta-
tion (G328V/W) was found in two patients, both with
H3.1-K27M. Mutations in ACVR1 (2 patients), FGFR1
(K697E or N98S) (two patients), MET (S572N) (1 patient),
and PIK3CA (E545K or I291M) (2 patients) were con-
served across all disease locations, as confirmed by ddPCR
(Additional file 4: Table S4). TP53 aberrations were ob-
served in three patients, including deletion and/or muta-
tion, across all disease sites in Patient 8 (Additional file 6:
Figure S2), who did not harbor a histone mutation, sug-
gesting TP53 as a potential driver. Varied TP53 aberra-
tions were also found across all disease locations in two
DIPGs with H3.3-K27M mutations, perhaps representing
a secondary but important genetic event.
Gene mutations demonstrating spatial heterogeneity
suggest secondary hits and poor potential for
monotherapy
PDGFRA point mutations occurred in two of eight pa-
tients. All disease sites in Patient 1 harbored two PDGFRA
mutations (S247L, Y555C), but only 1 of 6 disease sites in
Patient 3, which also exhibited high-level PDGFRA ampli-
fication, harbored a PDGFRA mutation (E229K) (Fig. 2).
PDGFRA gain/amplification was observed in five pa-
tients and showed notable intra-tumoral heterogeneity
(Additional file 7: Figure S3), suggesting clonality of this
recurrent genetic event. Other intra-tumorally hetero-
geneous mutations included ATRX, BCOR, and MYC.
Heterozygous ATRX mutations were found in Patients 6
(H2254R) and 8 (R2197L); while conserved across all
disease sites in Patient 8, the ATRX mutation in Patient
6 was absent in the metastatic compartment. A hetero-
zygous BCOR mutation (A535V) was found in a sin-
gle pontine site in Patient 2, and a heterozygous MYC
mutation (Q51L) was found in both pontine sites in
Patient 5 but was absent in the metastatic lesion. FISH
confirmed no MYC copy number gain in any tumor
samples from Patient 5.
Except for TP53, we did not detect somatic mutations
in genes involved in cell-cycle regulation, such as CDK4/
6, CCND1/2/3, CDKN2A/B or RB1. Amplification of
CDK4/6 or CCND1/2/3, more common in DIPG [14],
was not assessed. As expected, H3G34R/V mutations,
predominantly reported in hemispheric pediatric HGGs
[25], were also not found.
Discussion
Recent large-scale genomic studies have established the
inter-patient molecular complexity of pediatric HGGs [5,
10, 13, 14, 24]; however, limited understanding of spatial
subclonal architecture has impeded development of ef-
fective therapies. To our knowledge, we are the first to
Table 1 Clinical characteristics of patients with DIPG and mHGG
Patient Age at Diagnosis (years) Sex Primary Tumor Treatment at Diagnosis OS (months) Time to Autopsy (hours)
1 7.7 Male DIPG XRT + bevacizumab, irinotecan 24.4 19
2 2.9 Male DIPG XRT 32.2 17.5
3 4.3 Male DIPG XRT + HDAC inhibitor 11.2 15.5
4 4.4 Male DIPG XRT + HDAC inhibitor 11.5 4.8
5 3.5 Male DIPG XRT + EGFR inhibitor 16.8 5.5
6 23.3 Male DIPG XRT + HDAC inhibitor 13.4 8
7 12.3 Female DIPG XRT + PARP inhibitor, TMZ 11.8 20
8 15.1 Female Bi-thalamic HGG XRT + bevacizumab, TMZ, irinotecan 13.2 8
DIPG diffuse intrinsic pontine glioma, HGG high-grade glioma, TMZ temozolomide, HDAC histone deacetylase, PARP poly ADP ribose polymerase, EGFR epidermal
growth factor receptor, OS overall survival, XRT radiotherapy
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report multi-regional genetic analyses of matched pri-
mary, contiguous, and metastatic sites from DIPG and
mHGG. Disease-defining somatic mutations in H3F3A,
HIST1H3B, and ACVR1 were conserved across all tumor
locations, as were mutations affecting the (RTK)-PI3K-
MAPK pathway. However, other targetable molecular
aberrations, such as PDGFRA, were spatially heteroge-
neous. Findings from this study reiterate the distinct
biology between pediatric and adult HGG and are crit-
ical for establishing the role of diagnostic biopsy and
informing therapeutic strategy for these lethal pediatric
tumors.
Our findings confirm the propensity of DIPG and
mHGG for aggressive local and distant metastatic spread
(Fig. 1) and are consistent with our prior study in which
extra-brainstem and leptomeningeal disease was found
in 25 and 39 % of DIPGs from autopsy, respectively [1].
Caretti et al. similarly reported leptomeningeal involvement
in a quarter of DIPGs from autopsy [26]. Importantly, we
found histological evidence of metastatic disease by post-
mortem MRI in five cases in which tumor was not seen on
pre-mortem imaging or grossly at autopsy. Hence, disease
dissemination is prevalent, but in most cases appears late in
the disease course.
Spatial histological heterogeneity, frequently reported
in adult GBM [27, 28], was observed in all but one pa-
tient in our cohort (Fig. 1). Tissue from two DIPGs dem-
onstrated intra-pontine histologic variation, including
one with evidence of WHO grade II, III, and IV astrocy-
toma. We previously reported substantial histologic het-
erogeneity at various levels of the brainstem in DIPGs
from autopsy [1]; other autopsy studies have reported
limited histologic evaluation of one pontine site, most of
which were high-grade [12]. Metastatic lesions in our
A B C D E F G
Fig. 2 Intra-tumoral heterogeneity in a 4-year old male with DIPG (Patient 3). Each row represents a distinct disease location, including four different
areas in the primary tumor, one contiguous lesion in the right basal ganglia, and one metastatic leptomeningeal lesion. a H&Es of each tumor location
demonstrate WHO grade IV histology in all except the right basal ganglia lesion (WHO grade III), b P53 IHC demonstrates variable positivity, c PDGFRA
FISH demonstrates gain or amplification in 3 of 4 sites within the pontine tumor, gain in the contiguous right basal ganglia lesion, and amplification in
the metastatic leptomeningeal lesion, d PDGFRA ddPCR demonstrating PDGFRA mutation observed in the right posterior pons, e H3F3A was mutated
in all samples as demonstrated by Sanger sequencing, f sample location taken from fresh (“Primary Pons”, Row 1) or fixed tissue (remaining rows) at
autopsy corresponding to tumor location identified on post-mortem MRI imaging (g). Because post-mortem imaging was only performed on fixed
tissue, MRI imaging for the fresh tissue sample (“Primary Pons”, Row 1) was a pre-mortem MRI performed approximately 6 weeks prior to death
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cohort tended to be of lower histologic grade, a finding
consistent with our prior report [1]. While variation in
metastatic regions may represent sampling bias in areas
of lower tumor content, our finding of histologic hetero-
geneity within the densely tumor-packed pons in DIPG
reiterates the poor reliability of histopathological grading
for clinical stratification [1].
Significant temporal and spatial genetic and epigenetic
heterogeneity has been reported in adult HGG, including
regional variation of known driver mutations EGFR,
MET, PTEN, and CDK6 [19], as well as heterogeneity of
MGMT promoter methylation [29]. We are the first to
undertake comprehensive evaluation of the spatial gen-
omic landscape of DIPG and mHGG in children. The
most significant genomic discovery in DIPG and mHGG,
to date, has been that of recurrent mutations in evolu-
tionarily highly-conserved histone genes H3F3A and
HIST1H3B, resulting in replacement of lysine 27 by methio-
nine (K27M); these mutually exclusive somatic alterations
occur in approximately 80 % of DIPGs [14] and 50 % of
pediatric thalamic GBMs [4, 5]. Unlike the remarkable
intra-tumoral heterogeneity of driver mutations in adult
HGG, we confirmed the presence of heterozygous K27M
mutations in H3F3A or HIST1H3B in 100 % of tumor cells
across all disease compartments in four and three DIPGs,
respectively. This finding builds on prior reports demon-
strating consistently high allelic frequency of histone muta-
tions in all primary DIPG tumor cells using deep
sequencing [1, 30] and Kambhampati et al. finding of con-
servation of H3.3-K27M by IHC between the pons and
ventricular tumor extension in one DIPG patient from aut-
opsy [11]. Activating point mutations of ACVR1, present in
20–30 % of DIPGs [5, 14] and potentially targetable, were
also conserved across all tumor compartments. ACVR1
mutations were strongly associated with H3.1-K27M, as
previously described [14]. Furthermore, spatial conservation
of activating mutations of FGFR1, PIK3CA, and MET
supports the therapeutic relevance of targeting the
(RTK)-PI3K-MAPK pathway in DIPG. Spatial homo-
geneity of PIK3CA mutations, in particular, supports
their role as “founder mutations” in pediatric HGG,
as suggested by Wu et al. who discovered a common
PIK3CA mutation (Q546K) in multiple tumor sub-
clones derived from matched mHGG samples from
diagnosis and recurrence, suggesting not only spatial
but also longitudinal conservation [14]. Although TP53
aberrations were present across all tumor compartments,
the type and location of aberration varied suggesting that
they are critical, but likely secondary hits.
Similar to adult HGG, we observed subclonal variation
of PDGFRA aberrations in our cohort. Spatial heterogen-
eity was particularly evident for Patient 3 in whom amp-
lification was observed in three of six tumor locations
(Fig. 2). Fontebasso et al. similarly reported amplification
in one of five primary tumor sites in a treatment-naive
mHGG [5]. Interestingly, in Patient 3, one pontine site
bearing high-level PDGFRA amplification also harbored
a missense PDGFRA mutation (E229K); other sites with
PDGFRA gain/amplification were wild-type with suffi-
cient read coverage, suggesting later acquisition of this
activating mutation in PDGFRA-amplified clones. Our
findings are similar to Puget et al. who reported co-
occurrence of PDGFRA mutation and amplification in
three treatment-naïve DIPGs [31] but differ from a re-
port by Paugh et al. who found mutual exclusivity of
amplification and mutation in 26 and 5 % of 43 DIPGs,
respectively [32]. While it is apparent that PDGFRA mu-
tations and copy number changes arise in subclonal pop-
ulations, further studies are needed to determine their
temporal order and functional consequence.
Our description of the spatial genomic landscape of
DIPG and mHGG provides critical insight into the utility
of diagnostic biopsy and the biologic rationale behind se-
lection of therapeutic targets. Since the 1980s, imaging, ra-
ther than tissue, diagnosis has been the standard for DIPG
and most mHGGs. More recently, pre-treatment biopsy
has gained wider acceptance given the procedure’s low
morbidity [7, 8] and discovery of potentially actionable
genetic alterations that may inform therapy [5, 6, 14]. Des-
pite a notable shift in perspective in the pediatric neuro-
oncology community, ongoing concerns about intrinsic
heterogeneity, poor ability to decipher driver from by-
stander mutations, and sampling bias from the small tis-
sue yield of stereotactic biopsy have impeded uniform
implementation of pre-treatment biopsy to guide therapy.
Our study offers several important insights in favor of
diagnostic biopsy for DIPG and mHGG, including defini-
tive demonstration that disease-driving histone mutations
are intra-tumorally conserved. Several large clinico-
genomic studies have demonstrated the prognostic rele-
vance of H3 mutations [33, 34]. Ongoing acquisition of
pre-treatment tissue will allow refinement of histone
mutation-based risk groups and molecular signatures,
which have potential to elucidate oncogenic mechanisms
and resistance pathways. Our findings also demonstrate
that stereotactic biopsy of the safest intracranial disease
location offers bona fide representation of certain mo-
lecular aberrations, abrogating the need for multiple bi-
opsies at different sites of primary or metastatic tumor
to elucidate the molecular signature from which therapy
may be informed. Furthermore, the finding from this
and other reports [1, 32] that primary and metastatic
tumor sites may demonstrate variable histopathological
grades of astrocytoma (grades II-IV) without affecting
prognosis or defining risk groups also supports the rec-
ommendation to limit the number of biopsy locations.
Stereotactic biopsy of DIPG and mHGG should only be
performed at specialized medical centers with skilled
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pediatric neurosurgeons trained in such techniques to
minimize risk.
Development of adjuvant therapies should be focused
on targeting highly conserved genetic aberrations, which
likely represent true disease drivers. Promising preclinical
data demonstrating potent ability of demethylase inhibi-
tors (e.g. GSKJ4) to reverse the broad epigenetic dysregu-
lation and transcriptional signature induced by H3
mutations in DIPG support ongoing efforts for clinical
translation of such agents [3, 7, 8]. Grasso et al. also re-
ported compelling in vivo data demonstrating the thera-
peutic efficacy of multi-histone deacetylase inhibitor
panobinostat in H3-mutant DIPG xenografts, including
synergistic effect with GSKJ4 [5, 6, 14]. Ongoing work
with ALK2 inhibitors for ACVR1-mutant DIPG is also en-
couraging [10, 33, 34]. Therapies directed against subclo-
nal variants in DIPG and mHGG, such as PDGFRA,
should not be abandoned but rather pursued in combin-
ation instead of monotherapy. Therapeutic implications of
our findings should be formally tested in clinical trials
implementing biopsy-directed targeted therapies. Indeed,
target-based stratification based on biopsy results is
already underway in several ongoing clinical trials in
newly-diagnosed DIPGs (NCT01182350, NCT02233049).
Conclusion
Though conclusions from our study must be validated in
a larger cohort, preferably including diagnostic and aut-
opsy tissue for longitudinal comparison, our findings
have immediate clinical relevance for children with DIPG
and mHGG by supporting broader implementation of
diagnostic biopsy to facilitate ongoing biologic discovery,
further define molecular risk groups, and inform thera-
peutic strategy.
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